ARCH THERAPEUTICS, INC. Financials Arch Therapeutics, Inc.
Equities
ARTH
US03939W2089
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 USD | 0.00% |
|
+9.47% | -85.64% |
Valuation
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 67.53 | 41.41 | 33.28 | 30.77 | 4.795 | 6.096 |
| Enterprise Value (EV) 1 | 62.86 | 39.23 | 33.04 | 30.11 | 7.411 | 11.5 |
| P/E ratio | -13.3 x | -8.78 x | -6.94 x | -4.58 x | -0.87 x | -0.57 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 2,66,09,20,709 x | 30,63,77,140 x | 8,05,06,563 x |
| EV / Revenue | - | - | - | 2,60,32,77,907 x | 47,34,69,716 x | 15,18,85,320 x |
| EV / EBITDA | -8.44 x | -6.17 x | -6.18 x | -4.72 x | -1.3 x | -2.28 x |
| EV / FCF | -20 x | -13.6 x | -10.9 x | -11.9 x | -2.62 x | -8.59 x |
| FCF Yield | -4.99% | -7.34% | -9.18% | -8.38% | -38.1% | -11.6% |
| Price to Book | 49.4 x | -51.3 x | -22.3 x | -30 x | -1.14 x | -0.81 x |
| Nbr of stocks (in thousands) | 804 | 863 | 960 | 1,184 | 1,249 | 4,689 |
| Reference price 2 | 84.00 | 48.00 | 34.65 | 26.00 | 3.840 | 1.300 |
| Announcement Date | 18/12/18 | 19/11/19 | 11/12/20 | 17/12/21 | 28/12/22 | 15/02/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 0.0116 | 0.0157 | 0.0757 |
| EBITDA 1 | -7.444 | -6.364 | -5.346 | -6.375 | -5.706 | -5.043 |
| EBIT 1 | -7.45 | -6.372 | -5.353 | -6.377 | -5.709 | -5.044 |
| Operating Margin | - | - | - | -55,141.58% | -36,473.33% | -6,661.67% |
| Earnings before Tax (EBT) 1 | -4.814 | -4.548 | -4.691 | -6.24 | -5.276 | -6.983 |
| Net income 1 | -4.814 | -4.548 | -4.691 | -6.24 | -5.276 | -6.983 |
| Net margin | - | - | - | -53,960.07% | -33,707.22% | -9,221.43% |
| EPS 2 | -6.305 | -5.468 | -4.989 | -5.673 | -4.398 | -2.271 |
| Free Cash Flow 1 | -3.135 | -2.879 | -3.033 | -2.523 | -2.827 | -1.339 |
| FCF margin | - | - | - | -21,812.08% | -18,060.52% | -1,767.97% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18/12/18 | 19/11/19 | 11/12/20 | 17/12/21 | 28/12/22 | 15/02/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 2.62 | 5.41 |
| Net Cash position 1 | 4.67 | 2.18 | 0.23 | 0.67 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.4584 x | -1.072 x |
| Free Cash Flow 1 | -3.14 | -2.88 | -3.03 | -2.52 | -2.83 | -1.34 |
| ROE (net income / shareholders' equity) | -268% | -1,646% | 407% | 494% | 202% | 119% |
| ROA (Net income/ Total Assets) | -85.2% | -103% | -132% | -137% | -114% | -138% |
| Assets 1 | 5.65 | 4.421 | 3.543 | 4.562 | 4.643 | 5.052 |
| Book Value Per Share 2 | 1.700 | -0.9400 | -1.550 | -0.8700 | -3.360 | -1.600 |
| Cash Flow per Share 2 | 5.840 | 2.530 | 0.9900 | 1.920 | 0.6000 | 0.0500 |
| Capex 1 | 0.02 | - | 0 | 0 | - | 0 |
| Capex / Sales | - | - | - | 28.32% | - | 5.97% |
| Announcement Date | 18/12/18 | 19/11/19 | 11/12/20 | 17/12/21 | 28/12/22 | 15/02/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -85.64% | 46.22L | |
| +7.81% | 12TCr | |
| -5.61% | 1.1TCr | |
| +4.83% | 888.06Cr | |
| +34.96% | 545.48Cr | |
| -21.91% | 474.19Cr | |
| +8.00% | 343.51Cr | |
| -5.52% | 283.63Cr | |
| -10.23% | 215.38Cr | |
| -5.99% | 211.04Cr |
- Stock Market
- Equities
- ARTH Stock
- Financials Arch Therapeutics, Inc.